Hepatitis C Clinical Trials
Here are the 6 most popular medical studies for hepatitis c
Chemotherapy
MTL-CEBPA + Sorafenib for Liver Cancer
This trial is testing an experimental treatment (MTL-CEBPA) in combination with a standard of care treatment (sorafenib) in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
Rapid Point-of-Care Testing for Hepatitis C
This trial aims to study the effectiveness of rapid screening methods in diagnosing viral hepatitis infections compared to traditional methods. The goal is to provide same-day results to improve diagnosis rates and help healthcare providers engage with
Popular filter options for hepatitis c trials
HCV Clinical Trials
View 46 HCV medical studies.
Antiviral
HCV-Positive Organ Transplant Safety
This trial will test if it's safe to transplant organs from donors with HCV to recipients who don't have HCV. The recipient will take medication before and after the transplant. If successful, this could provide a large number of organs for transplant.
Hepatitis C Positive Liver Transplants for Liver Transplant Recipients
This trial is testing the safety and efficacy of transplanting livers from donors who are either positive or negative for the Hepatitis C virus. Treatment and prophylaxis will be administered to the recipients based on the donor's status.
Antiviral
Sofosbuvir/Velpatasvir for Kidney Transplant Recipients
This trial is testing the safety and efficacy of transplanting kidneys from donors who are either hepatitis C seropositive and non-viremic, or seropositive and viremic, to recipients who are seronegative. Treatment and prophylaxis will be administered using a transmission-triggered approach for the first scenario and a prophylaxis approach for the later scenario.
Opioid Use Disorder Clinical Trials
View 11 Opioid Use Disorder medical studies.
Behavioural Intervention
Mobile Hepatitis C Intervention for Hepatitis C
This trial will test a mobile intervention for hepatitis C virus (HCV) that includes access to syringes in order to reduce syringe sharing behavior and improve uptake of HCV testing and treatment in rural northern New England.
Behavioural Intervention
Transitional Care Program for HIV, Hepatitis C, and Substance Use Disorders
This trialwill test a medical program to help 220 ex-prisoners with HIV, HCV, or substance abuse. Results will be monitored for up to 6 months. #medical #prisoners #HIV #HCV #substanceabuse
NIATx Coaching for HIV, Hepatitis C, and Opioid Use Disorder Management
This trial will evaluate an intervention to introduce screening, evaluation and treatment of HIV/hep C/opioid use disorder in WV primary care clinics to improve health outcomes.
Hepatitis C Clinical Trials With No Placebo
View 55 hepatitis c medical studies that do not have a placebo group.
Antiviral
HCV-Positive Organ Transplant Safety
This trial will test if it's safe to transplant organs from donors with HCV to recipients who don't have HCV. The recipient will take medication before and after the transplant. If successful, this could provide a large number of organs for transplant.
Hepatitis C Positive Liver Transplants for Liver Transplant Recipients
This trial is testing the safety and efficacy of transplanting livers from donors who are either positive or negative for the Hepatitis C virus. Treatment and prophylaxis will be administered to the recipients based on the donor's status.
Antiviral
Sofosbuvir/Velpatasvir for Kidney Transplant Recipients
This trial is testing the safety and efficacy of transplanting kidneys from donors who are either hepatitis C seropositive and non-viremic, or seropositive and viremic, to recipients who are seronegative. Treatment and prophylaxis will be administered using a transmission-triggered approach for the first scenario and a prophylaxis approach for the later scenario.
View More Hepatitis C Trials
See another 34 medical studies focused on hepatitis c.
Frequently Asked Questions
Introduction to hepatitis c
What are the top hospitals conducting hepatitis c research?
In the realm of medical research, hospitals across the United States are diligently working to combat hepatitis c through innovative clinical trials. One notable institution leading the charge is Johns Hopkins University in Baltimore. With five ongoing hepatitis C trials and a commendable 18 completed studies throughout its history, this renowned university has been at the forefront of hepatitis C research since its first recorded trial in 2002. In Pittsburgh, UPMC (University of Pittsburgh Medical Center) is also making strides with three active hepatitis C trials and five prior investigations since their inaugural trial in 2008.
Meanwhile, Denver Health Medical Center is contributing to this vital field with two ongoing trials for hepatitis C, marking their recent entry into this area of study in 2019. Closer to Kentucky's heartland lies the University of Kentucky in Lexington - a facility that currently hosts two hepatisis C clinical trials while boasting four historical investigations dating back to their initial trial led by them in 2018.
Lastly but certainly not least, Mayo Clinic located amidst Arizona's scenic Scottsdale features prominently within these efforts too as it conducts another pair of active,hopeful clinical examinations regarding Hepatitis-C.Although comparatively newer than others yet equally impactful;Mayo Clinic initiated its earliest endeavor on such subjects six years ago,in2014 itself.
The combined dedication and expertise showcased by these esteemed hospitals signify a concerted effort toward conquering Hepatitis C – an infectious disease affecting millions worldwide.As each hospital contributes unique insights and therapeutic discoveries through rigorous scientific inquiry,it brings us closer towards finding more effective treatments leaving no stone unturned until we can eventually envision a future free from Hepatitis-C's grip
Which are the best cities for hepatitis c clinical trials?
When it comes to hepatitis c clinical trials, several cities have emerged as leading hubs for research and innovation. New york, with its 16 active trials, focuses on investigating Point of Care (POC) HCV Viremia testing and treatment options like Glecaprevir/Pibrentasvir (GLE/PIB). Baltimore follows closely behind with 9 ongoing studies examining patient-centered electronic apps and advanced testing methods such as the Xpert HCV Viral Load Finger-stick Point-of-Care test. Toronto boasts 8 active trials exploring different treatments including Glecaprevir/Pibrentasvir (GLE/PIB). These cities offer individuals struggling with hepatitis C access to cutting-edge clinical trials that propel the field forward in search of improved care outcomes.
Which are the top treatments for hepatitis c being explored in clinical trials?
In the realm of hepatitis c research, several promising treatments are currently being explored in clinical trials. Leading the way is sofosbuvir/velpatasvir, which has shown great potential with three active trials and five all-time hepatitis C studies since its first listing in 2017. Also making waves is Epclusa, boasting three active trials and nine all-time hepatitis C trials since its introduction in 2016. Last but not least, glecaprevir/pibrentasvir shines with two ongoing trials and six all-time studies focused on combating hepatitis C since it was first listed in 2016. With each trial providing valuable insights, researchers inch closer to finding effective solutions for those affected by this challenging disease.
What are the most recent clinical trials for hepatitis c?
The field of hepatitis c research continues to evolve with recent clinical trials offering new possibilities for treatment. One notable trial is Active, a phase 2 study that explores the efficacy of a potential treatment for hepatitis C. Another ongoing trial combines various drugs in phases 2 and 3 to assess their effectiveness against hepatitis C. Bemnifosbuvir and Ruzasvir, a phase 2 trial, also show promise as a potential treatment option. Additionally, a combination pill called Glecaprevir / Pibrentasvir is being investigated in phases 2 and 3. Lastly, a phase 4 trial examines the use of DAA therapy in combination with Bevacizumb and Atezolizumab for hepatitis C treatment. These trials represent the latest advancements in hepatitis C research, providing hope for improved outcomes and better treatment options for patients in the future.
What hepatitis c clinical trials were recently completed?
In recent years, several important clinical trials for hepatitis c have been successfully completed, representing significant progress in the field of treatment. Notably, a trial sponsored by the University of California, San Diego investigated glecaprevir/pibrentasvir (GLE/PIB) and concluded in May 2021. Additionally, the University of California, San Francisco conducted a trial involving Epclusa (SOF/VEL), which was completed in July 2020. These studies demonstrate ongoing efforts to find effective therapies for hepatitis C and highlight the dedication of researchers working towards improving patient outcomes.